The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.
Market Sentiment
The IPO drew intense retail interest with an oversubscription ratio of 399.08 times, signaling robust demand. However, the recorded hit rate of 0% — likely due to a full reallocation of the public tranche to the placing under the '机械B-无回补' mechanism — meant no public allocations were made, a highly atypical outcome. This divergence suggests that despite the enthusiasm, the allocation structure strongly favored institutional investors. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
The tier distribution reveals an unusual quirk: the 甲尾 (A-tail) group expected only 0.85 lots per application, while the 乙头 (B-head) group received a full 1.0 lot. This creates a perverse incentive where a larger B-head bid actually improved allocation efficiency over the highest A-tier, likely due to 'loose lot' rounding effects at the A/B boundary. The anomaly erodes the typical premium of smaller applications and warrants careful review of broker handling. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Mainland Chinese investors made up 65.6% of applicants, underscoring strong cross-border appetite for this Hong Kong robotics IPO. Men accounted for 64.9% and the average age was 41.4, reflecting a predominantly middle-aged male investor profile common in tech-focused offerings. This demographic skew may impact aftermarket liquidity and sentiment dynamics. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
About this page
This page shows Cofoe Medical (01187) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.